Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients

Ifeanyichukwu O. Onor, Sarah B. Todd, Erika Meredith, Sebastian D. Perez, Aneesh K. Mehta, G. Marshall Lyon, Stuart J. Knechtle, Steven I. Hanish

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) is a major cause of morbidity and mortality following solid organ transplantation (SOT). Two strategies, prophylactic, and preemptive have emerged for the prevention of CMV infection and disease after SOT. This retrospective chart review of two liver transplant cohorts: prophylactic and preemptive, compares the clinical impact of transitioning from prophylactic to preemptive strategy. The primary outcome is the incidence of CMV viremia at 3-and 6-months post-transplant. Secondary outcomes include: incidence of CMV tissue-invasive disease, acute cellular rejection, leukopenia and neutropenia, opportunistic infection rates, hospital readmission rates, and mortality at 3-and 6-months post-transplant. A total of 109 patients were included in the analysis. The incidence of CMV viremia was 4.9% and 50.0% (P < 0.001) in the prophylactic versus preemptive cohort, respectively, at 3 months post-transplant. The incidence of CMV viremia was 24.6% and 8.3% (P = 0.026) in the prophylactic versus preemptive cohort, respectively, at 6 months post-transplant. There were no statistical significant differences in the secondary outcomes between both cohorts. In conclusion, there is a statistical significant difference in time to onset of CMV viremia; however, the use of either prophylactic or preemptive strategy was not associated with significant negative clinical outcomes of CMV.

Original languageEnglish (US)
Pages (from-to)592-600
Number of pages9
JournalTransplant International
Volume26
Issue number6
DOIs
StatePublished - Jun 1 2013
Externally publishedYes

Fingerprint

Cytomegalovirus
Viremia
Liver
Transplants
Incidence
Organ Transplantation
Patient Readmission
Opportunistic Infections
Leukopenia
Cytomegalovirus Infections
Acute Disease
Hospital Mortality
Transplant Recipients
Neutropenia
Morbidity
Mortality

Keywords

  • Cytomegalovirus
  • liver transplantation
  • preemptive strategy
  • prophylactic strategy

ASJC Scopus subject areas

  • Transplantation

Cite this

Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients. / Onor, Ifeanyichukwu O.; Todd, Sarah B.; Meredith, Erika; Perez, Sebastian D.; Mehta, Aneesh K.; Marshall Lyon, G.; Knechtle, Stuart J.; Hanish, Steven I.

In: Transplant International, Vol. 26, No. 6, 01.06.2013, p. 592-600.

Research output: Contribution to journalArticle

Onor, Ifeanyichukwu O. ; Todd, Sarah B. ; Meredith, Erika ; Perez, Sebastian D. ; Mehta, Aneesh K. ; Marshall Lyon, G. ; Knechtle, Stuart J. ; Hanish, Steven I. / Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients. In: Transplant International. 2013 ; Vol. 26, No. 6. pp. 592-600.
@article{513915ebdf27451182060f3d7e3a39dc,
title = "Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients",
abstract = "Cytomegalovirus (CMV) is a major cause of morbidity and mortality following solid organ transplantation (SOT). Two strategies, prophylactic, and preemptive have emerged for the prevention of CMV infection and disease after SOT. This retrospective chart review of two liver transplant cohorts: prophylactic and preemptive, compares the clinical impact of transitioning from prophylactic to preemptive strategy. The primary outcome is the incidence of CMV viremia at 3-and 6-months post-transplant. Secondary outcomes include: incidence of CMV tissue-invasive disease, acute cellular rejection, leukopenia and neutropenia, opportunistic infection rates, hospital readmission rates, and mortality at 3-and 6-months post-transplant. A total of 109 patients were included in the analysis. The incidence of CMV viremia was 4.9{\%} and 50.0{\%} (P < 0.001) in the prophylactic versus preemptive cohort, respectively, at 3 months post-transplant. The incidence of CMV viremia was 24.6{\%} and 8.3{\%} (P = 0.026) in the prophylactic versus preemptive cohort, respectively, at 6 months post-transplant. There were no statistical significant differences in the secondary outcomes between both cohorts. In conclusion, there is a statistical significant difference in time to onset of CMV viremia; however, the use of either prophylactic or preemptive strategy was not associated with significant negative clinical outcomes of CMV.",
keywords = "Cytomegalovirus, liver transplantation, preemptive strategy, prophylactic strategy",
author = "Onor, {Ifeanyichukwu O.} and Todd, {Sarah B.} and Erika Meredith and Perez, {Sebastian D.} and Mehta, {Aneesh K.} and {Marshall Lyon}, G. and Knechtle, {Stuart J.} and Hanish, {Steven I.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1111/tri.12101",
language = "English (US)",
volume = "26",
pages = "592--600",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients

AU - Onor, Ifeanyichukwu O.

AU - Todd, Sarah B.

AU - Meredith, Erika

AU - Perez, Sebastian D.

AU - Mehta, Aneesh K.

AU - Marshall Lyon, G.

AU - Knechtle, Stuart J.

AU - Hanish, Steven I.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Cytomegalovirus (CMV) is a major cause of morbidity and mortality following solid organ transplantation (SOT). Two strategies, prophylactic, and preemptive have emerged for the prevention of CMV infection and disease after SOT. This retrospective chart review of two liver transplant cohorts: prophylactic and preemptive, compares the clinical impact of transitioning from prophylactic to preemptive strategy. The primary outcome is the incidence of CMV viremia at 3-and 6-months post-transplant. Secondary outcomes include: incidence of CMV tissue-invasive disease, acute cellular rejection, leukopenia and neutropenia, opportunistic infection rates, hospital readmission rates, and mortality at 3-and 6-months post-transplant. A total of 109 patients were included in the analysis. The incidence of CMV viremia was 4.9% and 50.0% (P < 0.001) in the prophylactic versus preemptive cohort, respectively, at 3 months post-transplant. The incidence of CMV viremia was 24.6% and 8.3% (P = 0.026) in the prophylactic versus preemptive cohort, respectively, at 6 months post-transplant. There were no statistical significant differences in the secondary outcomes between both cohorts. In conclusion, there is a statistical significant difference in time to onset of CMV viremia; however, the use of either prophylactic or preemptive strategy was not associated with significant negative clinical outcomes of CMV.

AB - Cytomegalovirus (CMV) is a major cause of morbidity and mortality following solid organ transplantation (SOT). Two strategies, prophylactic, and preemptive have emerged for the prevention of CMV infection and disease after SOT. This retrospective chart review of two liver transplant cohorts: prophylactic and preemptive, compares the clinical impact of transitioning from prophylactic to preemptive strategy. The primary outcome is the incidence of CMV viremia at 3-and 6-months post-transplant. Secondary outcomes include: incidence of CMV tissue-invasive disease, acute cellular rejection, leukopenia and neutropenia, opportunistic infection rates, hospital readmission rates, and mortality at 3-and 6-months post-transplant. A total of 109 patients were included in the analysis. The incidence of CMV viremia was 4.9% and 50.0% (P < 0.001) in the prophylactic versus preemptive cohort, respectively, at 3 months post-transplant. The incidence of CMV viremia was 24.6% and 8.3% (P = 0.026) in the prophylactic versus preemptive cohort, respectively, at 6 months post-transplant. There were no statistical significant differences in the secondary outcomes between both cohorts. In conclusion, there is a statistical significant difference in time to onset of CMV viremia; however, the use of either prophylactic or preemptive strategy was not associated with significant negative clinical outcomes of CMV.

KW - Cytomegalovirus

KW - liver transplantation

KW - preemptive strategy

KW - prophylactic strategy

UR - http://www.scopus.com/inward/record.url?scp=84878010896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878010896&partnerID=8YFLogxK

U2 - 10.1111/tri.12101

DO - 10.1111/tri.12101

M3 - Article

C2 - 23590709

AN - SCOPUS:84878010896

VL - 26

SP - 592

EP - 600

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 6

ER -